New trial
Phase I/II Trial Evaluates DM002 in Advanced Solid Tumors
- Trial ID
- NCT06751329 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Location
- 2 Locations
- Published in
- New in Oncology - May 7, 2025
Xadcera Biopharmaceutical (Suzhou) is conducting a first-in-human, open-label study to assess the safety, pharmacokinetics, and preliminary efficacy of DM002 in advanced solid tumors. The study features a dose-escalation phase across six dosing cohorts to identify the optimal dose for subsequent expansion.
More on NCT06751329
-
Trial result · Jul 8, 2026
DM002 (anti‑MUC1/HER3 BsADC; Topo‑I payload) Shows 20% PRs and 73% DCR in Early Solid-Tumor Readout
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings